N^G-(1-carboxymethyl)-L-arginine | 18416-86-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N^G-(1-carboxymethyl)-L-arginine
• 英文别名: N^α-carboxymethyl-L-arginine；N^α-Carboxymethyl-L-arginin；L-2-Carboxymethylamino-5-guanidino-valeriansaeure；Desmethyloctopin；L-Arginin-N^α-essigsaeure；Carboxymethylarginine；(2S)-2-(carboxymethylamino)-5-(diaminomethylideneamino)pentanoic acid
• CAS: 18416-86-9
• 化学式: C₈H₁₆N₄O₄
• 分子量: 232.239
• InChiKey: LJNDQMBPIQGDNB-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.1
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  151
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  L-精氨酸 、 氯乙酸 在 sodium carbonate 作用下， 生成 N^G-(1-carboxymethyl)-L-arginine
  参考文献：
  名称：

  Herbst; Swart, Journal of Organic Chemistry, 1946, vol. 11, p. 375

  摘要：

  DOI：

文献信息

• Novel breakers of advanced glycation endproducts
  申请人：City of Hope

  公开号：US20020002203A1

  公开（公告）日：2002-01-03

  Advanced glycation endproducts (AGEs) have been implicated in the pathogenesis of a variety of debilitating diseases such as diabetes, atherosclerosis, Alzheimer's and rheumatoid arthritis, as well as in the normal aging process. Seven compounds are here reported to be active in breaking AGE-protein cross-links. These compounds are 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid] (LR102); 4-[(3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoic acid (LR99); L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine] (LR20); 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylic acid (LR23); methylene bis [4,4′-(2-chlorophenylureidophenoxyisobutyric acid)] (LR90); 5-aminosalicylic acid (5-ASA); and metformin. These compounds may be used to reverse the debilitating effects of those diseases in which AGEs are formed.

  AGEs已被指称与多种令人痛苦的疾病的发病机制有关，如糖尿病、动脉粥样硬化、阿尔茨海默病和类风湿性关节炎，以及正常衰老过程。这里报道了七种化合物能够活跃地破坏AGE-蛋白交联。这些化合物分别是1,4-苯二[4-亚甲基氨基苯氧异丁酸]（LR102）；4-[(3,5-二氯苯脲基苯氧异丁酰]-4-氨基苯甲酸（LR99）；L-双-[4-(4-氯苯酰胺基苯氧异丁酰)半胱氨酸]（LR20）；4-(3,5-二氯苯脲基)苯氧异丁酰-1-氨基环己烷-1-羧酸（LR23）；亚甲基双 [4,4′-(2-氯苯脲基苯氧异丁酸)]（LR90）；5-氨基水杨酸（5-ASA）；和二甲双胍。这些化合物可用于逆转那些形成AGEs的疾病的令人痛苦影响。
• Ophthalmic formulation for the prevention and treatment of ocular conditions
  申请人：Chakshu Research, Inc.

  公开号：EP1972344A1

  公开（公告）日：2008-09-24

  An ophthalmic formulation is provided for the prevention and treatment of adverse ocular conditions, including presbyopia, arcus senilis, age-related macular degeneration, and other conditions associated with aging. The formulation is also useful in the prevention and treatment of other adverse ocular conditions such as those associated with oxidative and/or free radical damage within the eye; these conditions can involve a condition, disease, or disorder of the cornea, retina, lens, sclera, anterior segment, or posterior segment of the eye. In one embodiment, the formulation contains at least 0.6 wt.% of a biocompatible chelating agent, an effective permeation enhancing amount of an ophthalmic permeation enhancer such as methylsulfonylmethane (MSM), an anti-AGE agent, i.e., a compound that serves to reduce the presence of advanced glycation endproducts (AGEs) in the eye, and a pharmaceutically acceptable ophthalmic carrier suited to the particular formulation type (e.g., eye drops or ointments). Preferred components of the formulation are multifunctional and naturally occurring.

  本制剂是一种眼科制剂，用于预防和治疗眼部不良症状，包括老花眼、老年性角膜病、老年性黄斑变性以及其他与衰老相关的症状。该制剂还可用于预防和治疗其他眼部不良症状，如与眼内氧化和/或自由基损伤有关的症状；这些症状可能涉及角膜、视网膜、晶状体、巩膜、眼前节或眼后节的状况、疾病或紊乱。在一个实施方案中，制剂含有至少 0.6 重量百分比的生物相容性螯合剂、有效渗透量的眼科渗透促进剂（如甲基磺酰基甲烷 (MSM)）、抗衰老剂（即：一种可减少眼内自由基含量的化合物）、一种可减少眼内高级糖化终产物（AGEs）的化合物，以及一种适合特定制剂类型（如滴眼液或软膏）的药学上可接受的眼科载体。制剂的首选成分是多功能的天然成分。
• CARBOXYMETHYLARGININE PRODUCTION INHIBITOR AND COLLAGEN DENATURATION INHIBITOR
  申请人：Arkray, Inc.

  公开号：EP2452690A1

  公开（公告）日：2012-05-16

  The present invention provides a carboxymethylarginine production inhibitor for inhibiting the production of carboxymethylarginine and a collagen denaturation inhibitor for inhibiting the denaturation of collagen, both of which provide excellent safety. The carboxymethylarginine production inhibitor and the collagen denaturation inhibitor according to the present invention contain an extract of at least one plant selected from the group consisting of plants of Compositae Anthemis, Saururaceae Houttuynia, Rosaceae Crataegus, and Vitaceae Vitis. Specifically, they preferably contain an extract of at least one plant selected from the group consisting of Anthemis nobilis L., Houttuynia cordata Thunberg, Crataegus oxyacantha L., and Vitis vinifera L.

  本发明提供了一种用于抑制羧甲基精氨酸生成的羧甲基精氨酸生成抑制剂和一种用于抑制胶原蛋白变性的胶原蛋白变性抑制剂，二者都具有极佳的安全性。根据本发明，羧甲基精氨酸产生抑制剂和胶原蛋白变性抑制剂含有至少一种植物的提取物，这些植物选自菊科（Compositae Anthemis）、厥阴科（Saururaceae Houttuynia）、蔷薇科（Rosaceae Crataegus）和葡萄科（Vitaceae Vitis）植物组成的组。具体地说，它们最好含有至少一种植物的提取物，这些植物选自 Anthemis nobilis L.、Houttuynia cordata Thunberg、Crataegus oxyacantha L. 和 Vitis vinifera L. 组成的组。
• Immunoassay of carboxymethylarginine
  申请人：ARKRAY, Inc.

  公开号：EP2557423A1

  公开（公告）日：2013-02-13

  The present invention provides a new measuring method by which carboxymethylarginine can be measured with ease and with a high degree of precision. The measuring method is a method of measuring carboxymethylarginine in a sample. The method includes treating the sample with a pretreatment agent including urea; and measuring carboxymethyl arginine in the pretreated sample by an immunological method.

  本发明提供了一种新的测量方法，通过该方法可以轻松且高精度地测量羧甲基精氨酸。该测量方法是一种测量样品中羧甲基精氨酸的方法。该方法包括用包括尿素在内的预处理剂处理样品；以及用免疫学方法测量预处理样品中的羧甲基精氨酸。
• PHARMACEUTICAL COMPOSITION FORMED BY COMBINING PYRIDOXAMINE COMPOUND AND THIAMINE COMPOUND
  申请人：Project Pm Co. Ltd.

  公开号：EP3187185A1

  公开（公告）日：2017-07-05

  Vitamin B1 deficiency caused when a pyridoxamine compound is administered in a large amount is prevented and/or treated. A pharmaceutical composition formed by combining at least one pyridoxamine compound selected from the group consisting of pyridoxamine and pharmaceutically acceptable salts thereof and at least one thiamine compound selected from the group consisting of thiamine, derivatives thereof, and pharmaceutically acceptable salts thereof, is administered.

  预防和/或治疗大量服用吡多胺化合物引起的维生素 B1 缺乏症。 将至少一种选自吡哆胺及其药学上可接受的盐类的吡哆胺化合物与至少一种选自硫胺素、其衍生物及其药学上可接受的盐类的硫胺素化合物组合而成的药物组合物进行给药。